ES2162198T3 - Agentes estrogenos. - Google Patents

Agentes estrogenos.

Info

Publication number
ES2162198T3
ES2162198T3 ES97302576T ES97302576T ES2162198T3 ES 2162198 T3 ES2162198 T3 ES 2162198T3 ES 97302576 T ES97302576 T ES 97302576T ES 97302576 T ES97302576 T ES 97302576T ES 2162198 T3 ES2162198 T3 ES 2162198T3
Authority
ES
Spain
Prior art keywords
agents
strogen
compounds
fenil
iles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97302576T
Other languages
English (en)
Spanish (es)
Inventor
Chris P Miller
Bach D Tran
Michael D Collini
Arthur Attilio Santilli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27092026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2162198(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/833,271 external-priority patent/US5998402A/en
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2162198T3 publication Critical patent/ES2162198T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES97302576T 1996-04-19 1997-04-15 Agentes estrogenos. Expired - Lifetime ES2162198T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63397496A 1996-04-19 1996-04-19
US08/833,271 US5998402A (en) 1996-04-19 1997-04-04 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents

Publications (1)

Publication Number Publication Date
ES2162198T3 true ES2162198T3 (es) 2001-12-16

Family

ID=27092026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97302576T Expired - Lifetime ES2162198T3 (es) 1996-04-19 1997-04-15 Agentes estrogenos.

Country Status (26)

Country Link
EP (1) EP0802183B1 (OSRAM)
JP (1) JP4093611B2 (OSRAM)
KR (1) KR100480193B1 (OSRAM)
CN (1) CN1106383C (OSRAM)
AR (1) AR011503A1 (OSRAM)
AT (1) ATE206701T1 (OSRAM)
AU (1) AU710149B2 (OSRAM)
BR (1) BRPI9715334B8 (OSRAM)
CO (1) CO4900051A1 (OSRAM)
CY (2) CY2325B1 (OSRAM)
CZ (1) CZ291701B6 (OSRAM)
DE (2) DE69707189T2 (OSRAM)
DK (1) DK0802183T3 (OSRAM)
EA (1) EA001448B1 (OSRAM)
ES (1) ES2162198T3 (OSRAM)
FR (1) FR09C0048I2 (OSRAM)
HU (1) HU227077B1 (OSRAM)
IL (1) IL120701A (OSRAM)
LU (1) LU91608I2 (OSRAM)
MX (1) MX9702865A (OSRAM)
NL (1) NL300416I2 (OSRAM)
NO (2) NO309564B1 (OSRAM)
NZ (1) NZ314601A (OSRAM)
PT (1) PT802183E (OSRAM)
SK (1) SK281737B6 (OSRAM)
UA (1) UA48148C2 (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048797A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company Antithrombotic agents
WO1998048800A1 (en) 1997-05-01 1998-11-05 Eli Lilly And Company Antithrombotic agents
ID24568A (id) * 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
EP1082319B1 (en) * 1998-05-12 2006-09-13 Wyeth Benzocarbazole and indenoindole derived estrogenic agents
PT1076558E (pt) * 1998-05-15 2003-11-28 Wyeth Corp 2-fenil-1-¬4-(2-aminoetoxi)-benzil|-indole em combinacao com estrogenios
CA2331318A1 (en) * 1998-05-15 1999-11-25 James Harrison Pickar Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP0997465B1 (en) * 1998-10-30 2004-02-04 Eli Lilly And Company Azaindole derivatives and their use as antithrombotic agents
EP1159268A1 (en) * 1999-03-04 2001-12-05 American Home Products Corporation N-SUBSTITUTED BENzOYL INDOLES AS ESTROGENIC AGENTS
US6358943B1 (en) 1999-03-04 2002-03-19 American Home Products Corporation N-substituted indolines as estrogenic agents
US6380185B1 (en) 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
TWI220898B (en) * 1999-03-04 2004-09-11 Wyeth Corp N-substituted indolines as estrogenic agents
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
EA005371B1 (ru) * 1999-09-13 2005-02-24 Уайт Глюкопиранозидные конъюгаты 2-(4-гидроксифенил)-1-[4-(2-амин-1-илэтокси)бензил]-1h-индол-5-олов
AR035564A1 (es) * 2000-01-28 2004-06-16 Endorech Inc Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
WO2002003992A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
WO2002003989A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
EP1296674A2 (en) * 2000-07-06 2003-04-02 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
AU2001273144A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
WO2002003986A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
EP1990051A1 (en) 2000-07-06 2008-11-12 Wyeth Combinations of SSRI and estrogenic agents
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
AU2001271782A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
PT1401446E (pt) 2001-05-22 2005-05-31 Lilly Co Eli Derivados de tetrahidroquinolina para a inibicao de doencas associadas com a privacao de estrogenio ou com uma resposta fisiologica aberrante ao estrogenio endogeno
ES2259376T3 (es) 2001-05-22 2006-10-01 Eli Lilly And Company 1,2,3,4-tetrahidroquinolinas 2-sustituidas y sus derivados, composiciones y procedimientos.
KR20050010886A (ko) * 2002-06-13 2005-01-28 와이어쓰 바제독시펜 치료 방식
CA2490580C (en) 2002-07-22 2012-12-11 Eli Lilly And Company Selective estrogen receptor modulators containing a naphthalene group
JP4500689B2 (ja) 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的エストロゲン受容体モジュレーター
US7250440B2 (en) * 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
GT200500080A (es) 2004-04-07 2005-10-31 Polimorfo cristalino de acetato de bazedoxifeno
CA2561010A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of bazedoxifene acetate
WO2005100315A1 (en) 2004-04-08 2005-10-27 Wyeth Bazedoxifene ascorbate as selective estrogen receptor modulator
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000481A (es) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
JP2008509148A (ja) * 2004-08-05 2008-03-27 ワイス 塩酸ピピンドキシフェン一水和物の結晶多形
CN102357248A (zh) 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CN101977897A (zh) * 2008-02-11 2011-02-16 惠氏有限责任公司 制备乙酸巴多昔芬的多晶型a的方法
US8367665B2 (en) 2008-04-16 2013-02-05 Karo Bio Ab Estrogen receptor ligands
CN102395561A (zh) * 2009-04-13 2012-03-28 桑多斯股份公司 合成巴多昔芬乙酸酯及其中间体的方法
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
JP2013528626A (ja) 2010-06-16 2013-07-11 アンドルシェルシュ・インコーポレイテッド エストロゲン関連疾患を治療するまたは予防するための方法
US7968732B1 (en) 2010-09-07 2011-06-28 Divi's Laboratories, Ltd. Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole
WO2012037187A2 (en) 2010-09-14 2012-03-22 Dr. Reddy's Laboratories Ltd. Preparation of crystalline bazedoxifene and its salts
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
US9751835B2 (en) * 2013-05-15 2017-09-05 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3834824B1 (en) 2014-03-28 2025-10-22 Duke University Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
KR20190110400A (ko) 2018-03-20 2019-09-30 엠에프씨 주식회사 새로운 중간체를 이용한 바제독시펜의 제조방법
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU373940A3 (OSRAM) * 1970-01-21 1973-03-12
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
EP0639567A1 (en) * 1992-05-08 1995-02-22 Otsuka Pharmaceutical Factory, Inc. Indole derivative
DE69422450T2 (de) * 1993-06-29 2000-06-08 Takeda Chemical Industries, Ltd. Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
NL300416I2 (nl) 2010-02-01
CN1106383C (zh) 2003-04-23
NO309564B1 (no) 2001-02-19
CZ117597A3 (en) 1997-11-12
CY2009016I2 (el) 2010-07-28
EA001448B1 (ru) 2001-04-23
KR970069037A (ko) 1997-11-07
MX9702865A (es) 1998-05-31
HUP9700777A2 (hu) 1999-06-28
CZ291701B6 (cs) 2003-05-14
CN1170719A (zh) 1998-01-21
NO971815L (no) 1997-10-20
HU9700777D0 (en) 1997-06-30
HK1002863A1 (en) 1998-09-25
FR09C0048I1 (OSRAM) 2009-06-11
IL120701A (en) 2005-09-25
HUP9700777A3 (en) 2000-04-28
DE122009000061I1 (de) 2009-12-31
DK0802183T3 (da) 2002-02-04
AU1892097A (en) 1997-10-23
CO4900051A1 (es) 2000-03-27
IL120701A0 (en) 1997-09-30
PT802183E (pt) 2002-03-28
NO971815D0 (no) 1997-04-18
BR9715334B1 (pt) 2012-09-04
JPH1036346A (ja) 1998-02-10
JP4093611B2 (ja) 2008-06-04
NL300416I1 (nl) 2009-12-01
ATE206701T1 (de) 2001-10-15
EP0802183A1 (en) 1997-10-22
LU91608I2 (fr) 2009-11-23
SK47297A3 (en) 1997-11-05
AR011503A1 (es) 2000-08-30
SK281737B6 (sk) 2001-07-10
EA199700044A1 (ru) 1997-12-30
KR100480193B1 (ko) 2005-08-30
NO2009025I2 (no) 2010-11-22
UA48148C2 (uk) 2002-08-15
AU710149B2 (en) 1999-09-16
BRPI9715334B8 (pt) 2021-05-25
HU227077B1 (en) 2010-06-28
CY2009016I1 (el) 2010-07-28
EP0802183B1 (en) 2001-10-10
NZ314601A (en) 1999-09-29
DE69707189D1 (de) 2001-11-15
NO2009025I1 (no) 2009-11-30
FR09C0048I2 (OSRAM) 2010-06-11
DE69707189T2 (de) 2002-06-20
CY2325B1 (en) 2003-11-14

Similar Documents

Publication Publication Date Title
ES2162198T3 (es) Agentes estrogenos.
ES2179273T3 (es) N-bencil-2-fenilindolas como agentes estrogenicos.
HN1997000090A (es) Compuestos de piridilpirrol
ES2098140T3 (es) Liosferas que contienen gonadotropina.
HN1997000079A (es) Analogos de indazol sustituido.
HN1997000126A (es) Derivados de indazol
PT877750E (pt) 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
HN1997000023A (es) Derivados de lactama
HN1998000124A (es) Terapia de combinacion
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
HN1998000118A (es) 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
HN1996000101A (es) Terapia combinada para la osteoporosis
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
ES2183340T3 (es) Procedimiento para la preparcion de compuestos de 4-bromometil-bifenilo.
PT1086097E (pt) Compostos sulfonilbenzeno como agentes anti-inflamatorios/analgesicos
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
SE9801494D0 (sv) Novel use
HN1998000106A (es) Composiciones parenterales de alatroflaxacino
HN1998000199A (es) Agentes terapeuticos
HN1997000045A (es) Nuevos pirimido (1, 2 - 0) indoles
HN1998000028A (es) Otropisomeros de 3 heteroaril - 4 (3h) - quinazolinonas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 802183

Country of ref document: ES